Although cocaine is typically the second-most identified drug of abuse in drug-testing programs, there is surprisingly little quantitative information on excretion patterns following different routes of administration. This report details the urinary excretion and terminal elimination kinetics for cocaine and eight metabolites [benzoylecgonine (BZE), ecgonine methylester (EME), norcocaine (NCOC), benzoylnorecgonine (BNE), m-hydroxy-BZE (m-HO-BZE), p-hydroxy-BZE (p-HO-BZE), m-hydroxy-COC (m-HO-COC), and phydroxy-COC (p-HO-COC)]. Six healthy males were administered approximately equipotent doses of cocaine by the intravenous (IV), smoking (SM), and inhalation (IN) routes of administration. Urine specimens were collected for a minimum of three days after drug administration, screened by immunoassay (EMIT and TDX, 300 ng/mL), and analyzed by GC-MS. Mean Cmax values were generally as follows: BZE > EME > COC > BNE = p-HO-BZE > m-HO-BZE > m-HO-COC > NCOC > p-HO-COC. Elimination halflives for cocaine and metabolites were generally shorter following SM, intermediate after IV, and longest following IN administration. m-HO-BZE demonstrated the longest half-life (mean range 7.0-8.9 h), and cocaine displayed the shortest (2.4-4.0 h). Mean detection times were extended progressively by lowering cutoff concentrations. The maximum increases were approximately 55% at 50 ng/mL for the TDx assay (e.g., the detection time for the last consecutive positive changed from 32.8 h to 50.6 h for IV cocaine) and up to 39% for GC-MS at a cutoff concentration of 40 ng/ml. (e.g., the detection time for the last consecutive positive changed from 34.8 h to 48.1 h for IV cocaine). Sensitivity, specificity, and predictive values for EMIT and TDx were comparable at the 300-ng/mL cutoff concentration; but at lower cutoff concentrations, results that failed to meet administrative cutoff criteria. Detection of positive results was significantly enhanced through the use of the "Zero Threshold Criteria Method", a method developed by the authors to differentiate false-negatives from true-negatives. The method was based on establishing mean immunoassay response (MIR) baselines and variance (SD) in assays of drug-free specimens. Arbitrary thresholds (MIR + 0.5 SD, MIR + 1 SD, MIR + 2 SD) were utilized to evaluate all negative specimens. Apparent true positives were identified by the presence of BZE at or above 40% GC-MS cutoff concentrations. With these criteria, up to 111 false-negative specimens were confirmed as true-positive specimens; this was in addition to the 208 true positives detected at recommended cutoff concentrations. This represents a 50% increase in positive detection rates through the use of this methodology. Such methodology is recommended for further evaluation by drugtesting programs for enhancement of positive detection rates and as an alternative to creatinine testing for dealing with dilute specimens that test negative by initial tests, but contain quantifiable concentrations of drugs of abuse.
Introduction
A major contributing factor in the spread of the cocaine epidemic over the last two decades was the introduction of "crack" cocaine, a smokeable form of cocaine. The greater volatility of crack compared with cocaine salt (e.g., hydrochloride) facilitated administration by the smoking route. Further, smoked cocaine results in extremely rapid drug delivery to the blood stream without the use of needles. The smoked route has generally become the preferred route of administration for cocaine, but some individuals continue to prefer intravenous administration and others prefer the intranasal route. Oral administration of cocaine is less commonly encountered, but is of interest because of "doping claims" in which individuals claim to have ingested cocaine unknowingly in a drink or food product. These different routes of drug administration could lead to route-dependent differences in absorption, metabolism and excretion rates. Such differences could be reflected in urine drug-testing results.
Concurrently with the spread of the cocaine epidemic over the last two decades, a "cottage industry" has emerged on the Internet that promotes the sale and use of in vivo and in vitro adulterants, substitution products, and other paraphernalia that are designed to produce false-negative urine testing results. Many of the in vitro products are effective by relying upon ingestion of excess amounts of water along with the product as a means of"beating the drug test". Indeed, Cone et al. (1) demonstrated that consuming 2 quarts of water over a period of 2 h could be effective in converting true-positive cocaine urine resuits to false-negative tests.
Despite the growing prevalence of dilution, adulteration, and substitution products, urine testing for drugs of abuse remains a critical component of treatment (2) (3) (4) and workplace programs (5) . Most laboratories now routinely test creatinine and specific gravity for evidence of excessive dilution of urine specimens. Other suggestions have been made for improvements in urine testing methodology that would enhance detection of drug use, especially for those individuals who attempt in vivo or in vitro specimen dilution. One approach to the problem of excessive dilution involves lowering both the initial and confirmatory test cutoff concentrations. Such an approach is now under consideration by DHHS. The most recent guideline revision draft (Draft #4), released to the public in September 2001, proposes lowering the respective cocaine screening and confirmation cutoff concentrations for urine testing to 150 ng/mL (cocaine metabolite) and 100 ng/mL (benzoylecgonine, BZE). Others have proposed use of a "preconcentration step" for dilute specimens that would enhance detection (6) , but this approach is not feasible for use in large-scale drug testing laboratories. Clearly, there is currently a need for improved and enhanced drug-testing methodologies, considering the ease and rapidity with which individuals can manipulate urine cocaine metabolite concentrations.
To facilitate changes in drug-testing technology, a thorough knowledge of excretion patterns for cocaine and metabolites is needed. However, there is surprisingly little quantitative information available on excretion patterns of cocaine in urine by different routes of administration. To better understand the effect of the administration route, we studied the excretion patterns of cocaine and metabolites following intravenous, smoked, and intranasal administration. Six human subjects were administered cocaine under controlled dosing conditions in a closed-research unit. All urine specimens were collected and analyzed by conventional screening and confirmation methods. A preliminary report describing the metabolites identified in this study has been published (7) . The purpose of the current report was to provide a detailed description of the excretion patterns and pharmacokinetics of cocaine and eight metabolites following three routes of administration. The effect of lower cutoff concentrations on detection times was also evaluated. In addition, immunoassay results of urine specimens that tested negative (below conventional cutoff concentrations) were evaluated to determine if false-negative specimens containing BZE could be distinguished reliably from negative specimens that were drug-free or contained metabolite at or below 40% of the confirmation assay threshold cutoff concentrations.
Materials and Methods

Research subjects and study protocol
The participants were six healthy adult males who provided written informed consent and were paid for their participation. The protocol was approved by the Francis Scott Key Medical Center Institutional Review Board and adhered to Federal guidelines for the conduct of research with human subjects. All subjects had a history of intravenous and smoked cocaine use. Subjects participated in four experimental sessions in which cocaine or placebo was administered in a randomized, crossover design. Each session was separated by a minimum of three days. The design of the study and detailed procedures have been described (7) . Four cocaine/placebo (partial) combinations were administered as follows: (1) 
Collection and analysis of urine specimens
Urine specimens were collected before and ad libitum for a minimum of three days after each drug administration. After collection, the volume of each specimen was measured, and an aliquot was removed for determination of creatinine (Jaffe method), and for immunoassay monitoring of cocaine metabolite by Emit II TM (EMIT, Behring Diagnostics Corporation, Deerfield, IL) and TDX (Abbott Laboratories, Chicago, IL). The immunoassays used a 300-ng/mL cutoff concentration as recommended by DHHS. Specimens were frozen at -20~ until the time of analysis by gas chromatography-mass spectrometry (GC-MS). Specimens were analyzed by GC-MS over the subsequent year following completion of the study according to published procedures (7) for cocaine (COC), BZE, ecgonine methylester (EME), benzoylnorecgonine (BNE), norcocaine (NCOC), m-hydroxy-BZE (m-HO-BZE), p-hydroxy-BZE (p-HO-BZE), m-hydroxy-COC (m-HO-COC), p-hydroxy-COC (p-HO-COC), and anhydroecgonine methyl ester (AEME). The limit of detection (LOD) of this assay for all analytes was approximately 1 ng/mL. The concentration range of the calibration curves for cocaine, BZE and EME was 3.1-1000, and the range for all other analytes was 1.6-500 ng/mL.
Pharmacokinetic estimates of terminal elimination half-lives
The terminal elimination rates for cocaine and metabolites were calculated by the amount-remaining-to-be-excreted (ARE) method, also known as the sigma-minus method. This method requires complete collection of urine specimens during the monitoring period. The amount excreted is the product of the urine volume and analyte concentration. The amount excreted is summed over the entire period. The logarithm of the ARE is plotted on a semilogarithmic scale versus the time of urine collection. The slope of this line is -k/2.3 (where k is the elimination rate). The elimination half-lives for cocaine and metabolites were determined as 0.693/k.
Sensitivity, specificity, predictive value, and Receiver Operator Characteristic (ROC) assessments
Immunoassay performance was assessed by comparison of EMIT and TDX results to GC-MS quantitative results for BZE at different cutoff concentrations. Sensitivity, specificity, efficiency, predictive value (probability, based on sensitivity, specificity, and incidence of cocaine abuse in the population, that the result is a true positive or a true negative), and ROC were calculated according to published procedures (8, 9) .
Methods for detection of false-negative cocaine specimens
Specimen test results (immunoassay and GC-MS) were compared in order to determine if those specimens that tested negative by immunoassay at DHHS recommended and suggested cutoff concentrations contained BZE concentrations equal to or above 60 and 40 ng/mL by GC-MS. These cutoff concentrations were chosen to represent the 40% threshold in current use by DHHS for "retest" specimens and the corresponding threshold that would be used if the confirmation cutoff concentration for BZE were lowered to 100 ng/mL, respectively. The purpose of this evaluation was to determine if methodology could be developed that would reliably distinguish negative specimens, that is, specimens containing BZE below 40% cutoff concentration from apparent false-negative specimens that contained BZE at or above the 40% cutoff concentration thresholds.
Threshold criteria were arbitrarily set as the mean immunoassay responses (MIR) of drug-free specimens (specimens that contained < I ng/mL BZE by GC-MS) plus the variance (standard deviation, SD) of the immunoassay with drug-free specimens. This methodology is referred to as the "Zero Threshold Criteria Method". Three immunoassay threshold criteria for EMIT and TDX were utilized in the assessment as follows:
9 MIR + 0.5 SD 9 MIR + 1 SD 9 MIR + 2 SD Addition of 0.5 SD to the MIR includes approximately 38.3% of the variance in assay response with negative (drug-free specimens). Addition of 1 SD and 2 SD includes approximately 68.3% and 95.5% of the variance, respectively. All specimens that screened negative by immunoassay at the 300-ng/mL cutoff concentration were evaluated to determine if response rates were less than, equal to, or greater than these criteria. Specimens that tested below these arbitrary immunoassay threshold criteria were grouped into those specimens that contained < 60 ng/mL or < 40 ng/mL BZE by GC-MS [these specimens were designated as apparent true-negative specimens ("TN')] and those specimens that contained > 60 ng/mL or > 40 ng/mL BZE [designated as apparent false-negative specimens ("FN')]. Specimens that tested above the arbitrary immunoassay threshold criteria were grouped into those specimens
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Journal of Analytical Toxicology, Vol. 27, October 2003 that contained < 60 ng/mL or < 40 ng/mL BZE by GC-MS [these specimens were designated as apparent false-positive specimens CFP')] and those specimens that contained > 60 ng/mL or > 40 ng/mL BZE [designated as apparent true-positive specimens ("TP')]. It should be noted that false-positive and false-negative results were defined by whether specimens met administrative cutoff concentration criteria and not by whether there was true presence or absence of drug in the specimen.
Results
Urinary excretion patterns and pharmacokinetics of cocaine and metabolites in urine following different routes of administration COC and eight metabolites were measured in individual urine specimens by GC-MS following administration of single doses of cocaine by the IV, SM, and IN routes of administration. The doses selected for administration were considered approximately equipotent. The chemical structures and metabolic pattern for cocaine and the eight metabolites are illustrated in Figure 1 . Concentrations of COC and the eight metabolites are listed in Table I . For completeness, related measures (urine volume, creatinine concentration, immunoassay results) were also included. AEME, a pyrolysis product of cocaine, was also identified in a limited number of specimens following COC administration by the SM route. Details of specimens [subject, time of collection, AEME concentration (ng/mL)] containing AEME were as follows: E, 2.0 h, 76.9; F, 1.42 h, 27.5; J, 3.33 h, 8.0; J, 8.25 h, 7.0; and J, 9.5 h, 6.0.
Generally, urine specimens collected within ] h of cocaine administration contained cocaine and metabolite concentrations at less than peak concentrations or were negative. Peak concentrations of cocaine and metabolites occurred at variable times according to the nature of the metabolite and route of administration (see Table II ). A summary of Cm~, Tm~, and % dose for these metabolites has been published (7) . Generally, the mean time to peak concentration (Tmax) in urine was shortest for COC and NCOC (range 2.6-5. 
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rn-HO-BZE (range 6.9-10.2 h). Peak concentrations (Cmax) of COC and metabolites were highly variable. Mean Cm~ values generally followed the order as follows: BZE > EME > COC > BNE = p-HO-BZE > m-HO-BZE > m-HO-COC > NCOC > p-HO-COC. Mean % dose recovered from urine followed a similar pattern. Elimination half-lives were estimated for cocaine and metabolites based on their terminal elimination curves. Most estimates of half-life were based on six subjects and contained more than nine points on the excretion curve with the exceptions of COC, NCOC, m-HO-COC, and p-HO-COC. For p-HO-COC, there were insufficient data for estimation of half-life with the exception of two subjects following IN administration. The goodness of fit of the slope of the excretion curve * Abbreviations: SEM = standard error of mean; C~x = maximum urinary concentration; Trnax = time to maximum urinary concentration; R z = correlation coefficient of terminal urinary excretion curve.
t % Dose, Cmax, and Tmax data were previously reported (15) . % Dose was determined over three days. Data for the smoked route are based on N = 5 subjects.
was generally > 0.92 (R 2) with the exception of NCOC. Half-life estimates for cocaine and metabolites were generally shorter following SM administration, intermediate following IV administration and longest following IN administration, ra-HO-BZE demonstrated the longest half-life (mean range 7.0--8.9 h) and cocaine generally displayed the shortest half-life (2.4-4.0 h). Only one individual eliminated sufficient AEME following SM administration for estimation of its half-life (3.7 h).
Immunoassay and GC-MS detection times
Mean detection times to the last consecutively positive specimen and to the last positive are shown in Table III for EMIT, TDx, and GC-MS assays at selected cutoff concentrations. Detection times for the EMIT assay were determined at the 300-ng/mL cutoff concentration, and the TDx assay was evaluated at 300-, 150-, 100-, and 50-ng/mL cutoff concentrations. The GC-MS assay was evaluated at 150-, 100-, 60-, and 40-ng/mL cutoff concentrations. Cutoff concentrations were selected to illustrate the effect of lowering cutoff concentrations on detection times. Generally, detection times for the EMIT assay were comparable to the TDx assay at the 300-ng/mL cutoff concentrations. The effect of lowering the cutoff concentration for the TDx assay to 150, 100, and 50 (BZE equivalents, ng/mL) and the GC-MS assay to 100, 60, and 40 (BZE, ng/mL) extended detection times incrementally. Mean detection times for the last consecutive positive for the TDx assay were extended approximately 55% by lowering the cutoff concentration from 300 to 50 ng/mL (e.g., the detection time for the last consecutive positive changed from 32.8 h to 50.6 h for IV cocaine), whereas detection times for the GC-MS assay were extended from 18 to 39% by lowering the cutoff concentration from 150 to 40 ng/mL (e.g., the detection time for the last consecutive positive changed from 34.8 h to 48.1 h for IV cocaine). Sensitivity, specificity, efficiency, and predictive value of EMIT and TDx assays at recommended, proposed, and lower cutoff concentrations
The sensitivity, specificity, and efficiency of the EMIT and TDx immunoassays were determined at current recommended (300 ng/mL) cutoff concentrations. Additionally, TDx performance was evaluated at lower cutoff concentrations as shown in Table IV . The EMIT assay was only evaluated at the 300-ng/mL cutoff concentration because the assay was run in the qualitative mode. Predictive values for positive and negative results are shown based on prevalence rates of cocaine abuse of 1%, 5%, and 20%. The analysis was based on all positive and negative resuits ( Table I ). The total number of specimens evaluated was 474 for EMIT and 446 for TDx. Generally, EMIT and TDx results were comparable at a 300-ng/mL cutoff concentration. Semitivity, specificity and efficiency as well as predictive values were slightly better for the TDx assay at the 150-ng/mL cutoff concentration (compared to a 100-ng/mL cutoff concentration by GC-MS). At even lower TDx cutoff concentrations of 100 ng/mL and 50 ng/mL, specificity and predictive values of positive resuits were diminished indicating a somewhat higher risk of false positives occurring at these lower cutoff concentrations.
Detection of false-negative specimens by the Zero Threshold Criteria method
All specimens that tested negative by immunoassay in this study were evaluated to determine if threshold criteria for immunoassay response rate could be used to detect specimens that contained cocaine metabolite at concentrations below recommended immunoassay cutoff concentrations but sufficiently high in BZE concentration to be confirmed by GC-MS (i.e., 40% cutoff concentrations). For example, the EMIT (calibration standard = 0) and TDx assays for negative BZE specimens had MIRs (SD, N) of-38.07 (13.56 , N = 67) and 12.85 (16.45 , N = 54), respectively. Consequently, specimens that were negative by immunoassay with rates below or exceeding -24.5 for EMIT and 29.3 for TDx for the MIR + 1 SD criteria were evaluated to determine whether they were apparent TP, TN, FP, or FN by comparison to GC-MS concentrations of BZE at selected cutoff concentrations of 60 ng/mL and 40 ng/mL. It is reemphasized that all specimens in this evaluation initially tested negative by EMIT and TDx, but many contained BZE concentrations at levels above the sensitivity of the GC-M8 assay (approximately 1 ng/mL for BZE). Choices of the GC-MS cutoff concentrations at 60 ng/mL BZE and 40 ng/mL BZE were based on the assumption of testing at 40% of the currently recommended GC-MS cutoff concentration of 150 ng/mL and the proposed recommended cutoff concentration of 100 ng/mL.
The distribution of TP, FN, FP, and TN from this evaluation is shown in Table V . The number of TPs (additional true-positives not detected by immunoassay screening at 300 ng/mL) detected by these methods ranged from 29 to 111. Initially, screening at 300 ng/mL by EMIT and TDx produced a total of 208 TP results. Consequently, identification of up to 111 additional TP results yielded an increase of approximately 50% in the detection rate for positive specimens containing BZE. The results of the evaluation of the three threshold criteria were further investigated with ROC analysis and are shown in Figure  2 . EMIT demonstrated a low true-positive detection rate at the MIR + 2 SD threshold criteria, optimal performance (high truepositive detection rate and low false-positive rate) at MIR + 1 SD, and high false-positive detection rate at MIR + 0.5 SD. TDX performance was optimal at the MIR + 2 SD threshold criteria with little further change in true-positive detection rates, and an increase in false-positive rates at the MIR + 1 SD and MIR + 0.5 SD threshold criteria. Overall, the TDX performance appeared to be superior to EMIT at comparable threshold criteria and GC-MS cutoff concentrations for BZE.
Discussion
In the current study, the metabolic excretion patterns for cocaine following IV, SM, and IN administration of approximately equipotent single doses of cocaine were generally sireilar, but with some important differences. The recovery (% dose) and maximum concentrations (Cmax) of COC, BZE, EME, BNE, and related rnetabolites tended to be higher following administration by IV and IN routes compared to the SM route (see Table II ). It is likely that these differences were due to the loss of cocaine by pyrolysis during smoking (10) , resulting in a lower cocaine bioavailability by the SM route as compared with IV and IN administration. Excretion half-lives for COC and metabolites tended to be longer following IN as compared to the IV and SM routes. This trend appeared to be due to prolonged absorption of COC by the IN route compared to IV and SM administration (11) . As a consequence, detection times also tended to be longest for the IN route and shortest for the SM route (see Table III ). AEME was only detectable in low concentrations in a limited number of subjects following SM administration and did not appear to be useful in differentiating the SM route from other routes unless specimens were collected shortly after SM cocaine administration.
The complete description of excretion profiles for cocaine * See Methods for description of the Zero Threshold Criteria method. Abbreviations are as follows: "TP" = apparent true-positives; "FN" = apparent false-negatives; "FP" = apparent false-positives; and "TN" = apparent true-negatives, *Threshold criteria are listed for each assay; for example, 2 SD EMIT-v. GC-MS60 represents evaluation of immunoassay negative specimens (< 300 ng/mL) by the Zero Threshold Criteria method utilizing the MIR + 2 SD of negative specimens (zero BZE content by GC--/viS) with comparison to GC-MS results for BZE at a cutoff concentration of ~ 60 ng/mL. metabolites presented in Table I should facilitate interpretation of urine testing results for cocaine and metabolites. Urine testing for cocaine is used broadly in workplace, treatment and legal settings for multiple purposes. For example, Preston and colleagues used quantitative urinalysis for cocaine and BZE in urine as a means of assessing outcome for patients in treatment (12) and suggested its use in clinical trials monitoring (13) . Others have used baseline urine tests for cocaine metabolite taken prior to treatment as a means of predicting outcome (2, 4) . Documentation of cocaine metabolic patterns in urine should also assist in situations where cocaine "doping claims" have been made. Klette et al. (14) proposed measurement of nonhydrolytic cocaine metabolites (m-HO-BZE, p-HO-BZE, and BNE) in urine as a means of differentiation between adulteration or "doping" of urine specimens and true cocaine exposure. In the current study, it was noted that these metabolite~ exhibited the longest half-lives and were frequently detected along with BZE, albeit at lower concentrations and consequently shorter detection times. Detection of such metabolites, produced only by oxidative metabolic pathways and not by hydrolysis, would serve as irrefutable evidence that cocaine had been ingested by an individual. However, it should be noted that failure to detect such metabolites would not support allegations of adulteration or doping. A secondary goal of the current study was to determine if apparent false negative specimens could be reliably identified. Criteria for evaluation of immunoassay response were selected based on variance estimates of immunoassay response in testing drug-free specimens. This approach could be easily applied to any commercial immunoassay, but selected criteria may vary between assays. The use of MIR + 1 SD as threshold criteria was optimal for EMIT, whereas MIR + 2 SD was optimal for TDx. Also, there was a lower occurrence of "FPs" with the GC-MS confirmation cutoff concentration for BZE set at 40 ng/mL compared to 60 ng/mL. The combination of MIR + 2 SD with confirmation at 40 ng/mL for the TDx assay resulted in an efficiency greater than 90% and in detection of 107 additional positive specimens. The identification of 107 additional TP spec-linens represents an approximate 50% increase in detection rates of positive specimens over the original 208 TP specimens identified by screening and confirmation at recommended cutoff concentrations. This increase in detection rates for TP specimens was surprising and represents a significant improvement in methodology for detection of cocaine use. Use of this approach in drug-testing programs would likely result in an increase in detection rates for cocaine metabolite even at low prevalence rates. Presumably, such an approach would also result in an enhancement of detection rates for other drugs of abuse.
A related application of the proposed methodology for detection of apparent false-negative specimens would be for evaluation of dilute specimens (< 20 mg/dL creatinine, specific gravity < 1.003). Several studies have indicated that dilution attempts by drug-using individuals can be successful in producing negative results (1, 6) . Although the current study did not address dilution as a part of the evaluation, it would seem likely that false negative results produced by deliberate dilution could be detected by the methodology developed in this study.
Conclusions
Cocaine and metabolites appeared in urine rapidly following administration of single doses of cocaine by the IV, SM, and IN routes. BZE was the most abundant metabolite of the eight metabolites measured in this study. Detection times by immunoassay and GC-MS appeared to be slightly longer following the IN and IV routes compared to the SM route. COC had the shortest terminal elimination half-life, m-HO-BZE, a secondary metabolite of BZE, exhibited the longest half-life but was in lower abundance than BZE. Lower cutoff concentrations for immunoassay and GC-MS produced longer detection times and greater numbers of positive specimens. New methodology developed in this study, based on immunoassay response rates with drug-free specimens, was surprising effective in detection of apparent false-negative specimens. Application of the methodology resulted in an approximate 50% increase in the detection rate for cocaine metabolite in urine. Such methodology is recommended for further evaluation by drug-testing programs for enhancement of assay detection rates and in dealing with dilute specimens suspected of containing drugs of abuse.
